Streetbeat News

RLMD

Relmada Therapeutics, Inc.

https://www.relmada.com

Industry

Biotechnology

Relmada Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing various products for the treatment of central nervous system (CNS) diseases and other disorders. Its lead product candidate is Esmethadone (d-methadone, dextromethadone, and REL-1017), a new chemical entity and N-methyl-D-aspartate receptor antagonist that is in Phase 3 clinical trials for the adjunctive or monotherapy treatment of major depressive disorder in adults. The company was founded in 2004 and is headquartered in Coral Gables, Florida.

Open

3.40

Mkt cap

98M

Volume

83K

High

3.44

P/E Ratio

-1.14

52-wk high

7.22

Low

3.22

Div yield

N/A

52-wk low

1.88

Goldman Sachs has downgraded Relmada Therapeutics (NASDAQ:RLMD) from Neutral to Sell and lowered the price target from $3 to $2.

Portfolio Pulse from Benzinga Newsdesk

June 05, 2024 | 12:22 pm

Relmada Therapeutics reported Q1 2024 GAAP EPS of $(0.72), surpassing the $(0.84) estimate, marking a 17.24% improvement over last year's $(0.87) per share loss.

Portfolio Pulse from Benzinga Newsdesk

May 08, 2024 | 9:21 pm

Relmada Therapeutics reported a Q4 EPS loss of $(0.84), missing the consensus estimate of $(0.83) by 1.2%. This represents a 34.38% improvement over the $(1.28) per share loss from the same period last year.

Portfolio Pulse from Happy Mohamed

March 19, 2024 | 8:33 pm

Relmada Therapeutics (NASDAQ:RLMD) reported Q4 earnings with an EPS of $-0.84, missing estimates by -1.0% and showing no revenue change from the previous year. Last quarter, the company beat EPS estimates which led to a 0.0% change in share price the following day.

Portfolio Pulse from Benzinga Insights

March 19, 2024 | 8:30 pm

Relmada Therapeutics reported its 2023 earnings per share (EPS) at $(3.28), indicating a loss per share for the year.

Portfolio Pulse from Benzinga Newsdesk

March 19, 2024 | 8:22 pm

Earnings reports for March 19, 2024, include a mix of projected profits and losses across various sectors. Notable companies like Tencent Music, HUYA, Caleres, XPeng, and ZTO Express are among those reporting. The reports span from technology and retail to biotech and mining, indicating a broad market impact.

Portfolio Pulse from Benzinga Insights

March 19, 2024 | 10:06 am

Relmada Therapeutics (NASDAQ:RLMD) is scheduled to release its quarterly earnings report on March 19, 2024, with an expected EPS of $-0.83. Historical data shows mixed reactions to past earnings, with a notable 132.23% stock increase over the last 52 weeks. Investors are advised to watch for the company's guidance for future growth.

Portfolio Pulse from Benzinga Insights

March 18, 2024 | 2:01 pm

Insiders at Relmada Therapeutics, Processa Pharmaceuticals, and PaySign have recently made significant stock purchases. These transactions indicate insider confidence in the companies' prospects. Processa Pharmaceuticals announced a public offering, Relmada Therapeutics reported a narrower quarterly loss, and PaySign posted better-than-expected sales.

Portfolio Pulse from Avi Kapoor

February 01, 2024 | 1:42 pm

Relmada Therapeutics CEO Sergio Traversa has purchased 100,000 shares of the company at an average price of $3.87 per share, as reported in a Form 4 filing on Wednesday.

Portfolio Pulse from Charles Gross

January 31, 2024 | 11:57 pm

Mobileye Global Inc. (MBLY) shares plummeted over 23% after issuing preliminary FY23 financial results and initial 2024 guidance, which were below the previous implied guidance. Wolfe Research analyst Shreyas Patil downgraded the stock from Outperform to Peer Perform. Other stocks experienced significant movement in Thursday's mid-day session, with various companies reporting gains due to positive developments, collaborations, and strategic reviews, while others faced declines due to public offerings, corporate updates, and preliminary financial results.

Portfolio Pulse from Avi Kapoor

January 04, 2024 | 6:37 pm

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.